<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">Recently, the mixture of three drugs, lopinavir, oseltamivir and ritonavir has been proposed to mitigate the virulence to a good extent in COVID-19 affected patients. Hence, these drugs are often explored further for drug repurposing against the successful inhibition of COVID-19 [
 <xref ref-type="bibr" rid="CR90">90</xref>]. A randomized controlled experiment of lopinavir/ritonavir showed no visible clinical or virologic benefit, and drugâ€“drug interactions and consequences further limit its utility [
 <xref ref-type="bibr" rid="CR91">91</xref>]. Oseltamivir demonstrated limited activity against SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR91">91</xref>].
</p>
